Compare Progressive Corp (PGR) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Progressive Corp vs Repligen Corporation Common Stock — how do they compare? Progressive Corp trades at $215.77 (market cap $129.36B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: Progressive Corp is far larger — about 11.6× Repligen Corporation Common Stock's market cap, and Progressive Corp pays a 0.18% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Progressive Corp for 81 Days and Repligen Corporation Common Stock for 0 Days on average.
| PGR | RGEN | |
|---|---|---|
Market Cap | $129.36B | $11.14B |
Volume | 3,501,619 | 1,259,263 |
Sector | Financials | Health |
52-Week High | $236.18 | $194.57 |
52-Week Low | $190.40 | $102.87 |
Typical Hold Time | 81 Days | 0 Days |
Enterprise Value | $137.57B | $11.02B |
Dividend Yield | 0.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PGR trades at $213.46, down 3.1% on the day, amid mixed earnings results with recent Q3 2026 miss. The stock shows strong fundamentals with revenue growth from $49.6B in 2022 to $87.6B in 2025 and net income margin of 12.85%. Technicals are bullish with moving averages supporting upside, while RSI levels indicate potential overbought conditions. Recent news highlights Progressive's telematics edge and inclusion in dividend-focused articles.
Outlook remains positive with analyst consensus target of $222.23 implying ~4% upside. Key opportunities include sustained underwriting strength and dividend reliability, but risks involve competitive pressures in auto insurance and earnings volatility. The stock's valuation at P/E of 11.18 appears reasonable relative to profitability metrics.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Progressive Corp
Progressive underwrites private and commercial auto insurance and specialty lines
Read more on PGR →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
